about
In vitro cell culture model for toxic inhaled chemical testingTreatment with the catalytic metalloporphyrin AEOL 10150 reduces inflammation and oxidative stress due to inhalation of the sulfur mustard analog 2-chloroethyl ethyl sulfide.Intratracheal heparin improves plastic bronchitis due to sulfur mustard analog.Airway obstruction due to bronchial vascular injury after sulfur mustard analog inhalation.Airway tissue plasminogen activator prevents acute mortality due to lethal sulfur mustard inhalationSarcoendoplasmic reticulum Ca(2+) ATPase. A critical target in chlorine inhalation-induced cardiotoxicity.Tissue plasminogen activator prevents mortality from sulfur mustard analog-induced airway obstruction.Sulfur mustard inhalation: mechanisms of injury, alteration of coagulation, and fibrinolytic therapy.Innate and acquired immunity to herpes simplex virus type 1.Antifibrinolytic mechanisms in acute airway injury after sulfur mustard analog inhalationTissue factor pathway inhibitor prevents airway obstruction, respiratory failure and death due to sulfur mustard analog inhalation.From the Cover: Catalytic Antioxidant Rescue of Inhaled Sulfur Mustard Toxicity.Bronchiolitis Obliterans and Pulmonary Fibrosis After Sulfur Mustard Inhalation in Rats.Oxygen Administration Improves Survival but Worsens Cardiopulmonary Functions in Chlorine-exposed Rats.From the Cover: ImpairedProliferation and Differentiation of the Conducting Airway Epithelium Associated With Bronchiolitis Obliterans After Sulfur Mustard Inhalation Injury in Rats.Percutaneous thoracic duct intervention to treat plastic bronchitis related to Fontan palliation.Reply to: Comment on "Bronchiolitis Obliterans and Pulmonary Fibrosis after Sulfur Mustard Inhalation in Rats"
P50
Q33719383-34AEC495-4502-4DDA-A53E-21545E4ABD72Q33762018-6ED71629-175B-4F4D-97FA-E1B5A26FAEDAQ34276253-FA9617EA-BDA7-4F23-BC22-FD32CCC0BC48Q34535026-C52AA80B-2F3B-4777-8C5B-25AEEDE370BCQ34760271-CEAE874D-164C-4088-869B-E5401041816DQ35816343-DCFF97F2-40CA-4E8F-AA49-7BE812E8FC4EQ36842960-F82F2D71-7EC1-402A-A3AA-B0863A5531F4Q38888243-2D7D7175-E5A1-4160-8624-D2610955AB55Q41084725-54450507-CC64-4D55-8865-C55339049B02Q42057115-904F9CAA-C5EC-4D17-9B11-D5C897FF89AAQ42629815-6B1C310F-89FE-4E25-83C9-88B80216A72FQ46492305-9A90097A-1DF7-4945-845C-25475C971F16Q47662470-069E5CD7-D98E-48BC-829D-6BD2EF8751EFQ47791356-39C460DF-C7C9-44D8-A603-66C9C4538809Q47921807-4AA7E438-4A3D-4441-B8DD-31A4B05D3448Q48133740-755E0E75-0252-4A92-806F-47B21E1804EEQ90685047-30AFB7BE-9545-4328-B5BC-2D8A7932C9C1
P50
description
researcher ORCID ID = 0000-0003-4981-9634
@en
name
Livia A Veress
@ast
Livia A Veress
@en
Livia A Veress
@nl
type
label
Livia A Veress
@ast
Livia A Veress
@en
Livia A Veress
@nl
prefLabel
Livia A Veress
@ast
Livia A Veress
@en
Livia A Veress
@nl
P31
P496
0000-0003-4981-9634